Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT03331601
PHASE2

Evaluation of 68-GaNOTA-Anti-HER2 VHH1 Uptake in Brain Metastasis of Cancer Patients

Sponsor: Universitair Ziekenhuis Brussel

View on ClinicalTrials.gov

Summary

This study investigates the uptake of the radiopharmaceutical 68-GaNOTA-Anti-HER2 VHH1 in brain metastasis using PET/CT imaging. Patients with HER2-positive and HER2-negative cancer will be included and the uptake in their lesions will be compared. Optional 68-GaNOTA-Anti-HER2 VHH1 scans may be performed during or after treatment, at time points 12±6 weeks and 24±9 weeks after the first scan.

Official title: Evaluation of 68GaNOTA-Anti-HER2 VHH1 Uptake in Brain Metastasis of Cancer Patients

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

30

Start Date

2017-10-16

Completion Date

2026-12

Last Updated

2024-04-24

Healthy Volunteers

No

Interventions

DRUG

68GaNOTA-Anti-HER2 VHH1

Injection of the radiopharmaceutical and PET/CT 90 min post injection

Locations (1)

Uz Brussel

Brussels, Belgium